Payment overview · 2025
General Payments
$1,148.64
70 reported records · 18 companies
Healthcare provider profile · identity verified
Aaron Thomas Groth, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · SPRINGFIELD, OH · NPI 1508809021
Verified facts
What the public records show
CMS Open Payments records show Aaron Thomas Groth, M.D. received $1,148.64 in general payments during 2025 across 70 reported records.
ABBVIE INC. accounted for 19.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Linzess, Mounjaro, Ozempic, Paxlovid, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 152 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 152 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $225.41 | 19.6% | 17 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $220.09 | 19.2% | 16 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $95.22 | 8.3% | 5 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $93.58 | 8.2% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $79.99 | 7.0% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $78.02 | 6.8% | 4 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $72.40 | 6.3% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $53.32 | 4.6% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $43.99 | 3.8% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $41.06 | 3.6% | 2 | 2025 |
| bioMerieux Inc | Unresolved — no canonical attribution shown | $23.64 | 2.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.13 | 1.9% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $20.10 | 1.8% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $18.91 | 1.6% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $16.53 | 1.4% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $15.99 | 1.4% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $14.69 | 1.3% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $13.57 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,148.64 | 70 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $109.03 | 11 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $93.58 | 5 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $90.48 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $79.99 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $72.94 | 5 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $72.40 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $69.76 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $69.70 | 7 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $64.98 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $61.99 | 7 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $50.93 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $50.93 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $47.36 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $46.61 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $43.99 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $41.06 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $39.28 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $31.41 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $29.92 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $29.92 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $23.40 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $20.10 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $19.06 | 1 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $18.91 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $16.53 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $15.99 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $14.69 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $13.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 152 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 46 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 42 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 73 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 16 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
46 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
127 | 35 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
152 | 38 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
152 | 38 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
42 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
80 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
73 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
137 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 678 | 190 |
| Amlodipine Besylate | Amlodipine Besylate | 626 | 163 |
| Levothyroxine Sodium | Levothyroxine Sodium | 580 | 144 |
| Losartan Potassium | Losartan Potassium | 538 | 143 |
| Atorvastatin Calcium | Atorvastatin Calcium | 529 | 152 |
| Duloxetine Hcl | Duloxetine Hcl | 446 | 110 |
| Gabapentin | Gabapentin | 428 | 90 |
| Omeprazole | Omeprazole | 419 | 119 |
| Lisinopril | Lisinopril | 342 | 91 |
| Hydrochlorothiazide | Hydrochlorothiazide | 335 | 88 |
| Fluticasone Propionate | Fluticasone Propionate | 307 | 128 |
| Furosemide | Furosemide | 283 | 67 |
| Pantoprazole Sodium | Pantoprazole Sodium | 251 | 74 |
| Metformin Hcl Er | Metformin Hcl | 227 | 60 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 218 | 41 |
| Metformin Hcl | Metformin Hcl | 217 | 59 |
| Tamsulosin Hcl | Tamsulosin Hcl | 213 | 64 |
| Metoprolol Succinate | Metoprolol Succinate | 210 | 63 |
| Famotidine | Famotidine | 196 | 68 |
| Lorazepam | Lorazepam | 189 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 183 | 66 |
| Pravastatin Sodium | Pravastatin Sodium | 180 | 50 |
| Pregabalin | Pregabalin | 178 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 170 | 40 |
| Jardiance | Empagliflozin | 152 | 38 |
| Montelukast Sodium | Montelukast Sodium | 146 | 45 |
| Sertraline Hcl | Sertraline Hcl | 146 | 42 |
| Tramadol Hcl | Tramadol Hcl | 145 | 43 |
| Glimepiride | Glimepiride | 139 | 30 |
| Eliquis | Apixaban | 137 | 29 |
| Meloxicam | Meloxicam | 137 | 27 |
| Trazodone Hcl | Trazodone Hcl | 133 | 39 |
| Buspirone Hcl | Buspirone Hcl | 131 | 34 |
| Synthroid | Levothyroxine Sodium | 127 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 126 | 44 |
| Carvedilol | Carvedilol | 125 | 33 |
| Prednisone | Prednisone | 124 | 84 |
| Alendronate Sodium | Alendronate Sodium | 122 | 31 |
| Fluoxetine Hcl | Fluoxetine Hcl | 114 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 109 | 28 |
| Simvastatin | Simvastatin | 108 | 30 |
| Tradjenta | Linagliptin | 102 | 28 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 99 | 20 |
| Celecoxib | Celecoxib | 98 | 31 |
| Warfarin Sodium | Warfarin Sodium | 98 | 18 |
| Memantine Hcl | Memantine Hcl | 97 | 18 |
| Solifenacin Succinate | Solifenacin Succinate | 94 | 22 |
| Potassium Chloride | Potassium Chloride | 88 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 83 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 82 | 19 |
| Trulicity | Dulaglutide | 80 | 13 |
| Alprazolam | Alprazolam | 77 | 11 |
| Azelastine Hcl | Azelastine Hcl | 74 | 39 |
| Ozempic | Semaglutide | 73 | 21 |
| Benazepril Hcl | Benazepril Hcl | 71 | 11 |
| Donepezil Hcl | Donepezil Hcl | 71 | 15 |
| Valsartan | Valsartan | 71 | 18 |
| Allopurinol | Allopurinol | 70 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 70 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 65 | 16 |
| Atenolol | Atenolol | 61 | 17 |
| Clonazepam | Clonazepam | 60 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 60 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 59 | 54 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 54 | suppressed |
| Mirtazapine | Mirtazapine | 53 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 52 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 50 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | 20 |
| Breo Ellipta | Fluticasone/Vilanterol | 47 | 12 |
| Eszopiclone | Eszopiclone | 46 | suppressed |
| Linzess | Linaclotide | 46 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 45 | 11 |
| Naproxen | Naproxen | 44 | 12 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 43 | 17 |
| Aripiprazole | Aripiprazole | 43 | 12 |
| Mounjaro | Tirzepatide | 42 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 41 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 41 | suppressed |
| Ibuprofen | Ibuprofen | 40 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 40 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 39 | 35 |
| Clotrimazole | Clotrimazole | 38 | 21 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | 11 |
| Propranolol Hcl | Propranolol Hcl | 38 | 11 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 36 | suppressed |
| Cilostazol | Cilostazol | 36 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 36 | suppressed |
| Methylprednisolone | Methylprednisolone | 36 | 33 |
| Spironolactone | Spironolactone | 35 | 12 |
| Fluocinonide | Fluocinonide | 34 | 22 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 34 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 33 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 33 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 31 | 27 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 31 | 11 |
| Bupropion Xl | Bupropion Hcl | 30 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Januvia | Sitagliptin Phosphate | 30 | 11 |
| Finasteride | Finasteride | 29 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 28 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 26 | suppressed |
| Lansoprazole | Lansoprazole | 25 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Ramipril | Ramipril | 24 | suppressed |
| Temazepam | Temazepam | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 22 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 15 |
| Valacyclovir | Valacyclovir Hcl | 21 | 11 |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 20 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Ezetimibe | Ezetimibe | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Praluent Pen | Alirocumab | 19 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 18 | suppressed |
| Nystatin | Nystatin | 18 | 12 |
| Primidone | Primidone | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Gemtesa | Vibegron | 17 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 13 |
| Glipizide | Glipizide | 16 | suppressed |
| Jantoven | Warfarin Sodium | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | 15 |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Risedronate Sodium | Risedronate Sodium | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Galantamine Er | Galantamine Hbr | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 15 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Testosterone | Testosterone | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Azithromycin | Azithromycin | 13 | 13 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 13 | suppressed |
| Glyburide | Glyburide | 13 | suppressed |
| Roflumilast | Roflumilast | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Carbatrol | Carbamazepine | 12 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Zolmitriptan | Zolmitriptan | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,148.64 · 70 records | ABBVIE INC. | CREON, DUPIXENT, Dexcom G6 Transmitter, EVENITY, FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, KISUNLA, Korlym, LINZESS, MOUNJARO, NEXLETOL, NURTEC ODT, Ozempic, PAXLOVID, QULIPTA, REPATHA, REXULTI, Rybelsus, TONMYA, UBRELVY, UNITHROID, VRAYLAR, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error